UK: Genentech’s Herceptin Purification Patent Fails To Pass The Acid Test

Last Updated: 20 May 2014
Article by Zain Odho and Stephen Duffield

The UK's High Court has decided that Genentech's patent relating to a composition of Herceptin with reduced acidic variant content is invalid.


Herceptin is the world's tenth best-selling drug, with sales of US$ 6.9 billion. Genentech held a (recently expired) patent protecting the monoclonal antibody trastuzumab, the active ingredient in Herceptin. The supplementary protection certificate (Europe's mechanism for patent term extension for pharmaceutical products) based on this patent protecting trastuzumab expires on 28th July 2014.

Hospira aims to sell a generic of Herceptin in Europe after this date (it has already obtained approval for the generic in South Korea, so Hospira appears well prepared to roll it out in Europe). Genentech, however, also owns two further Herceptin patents with later expiry dates, which were at suit in this action. The decision regarding the first patent was reviewed in a related article, published here last week. This article focusses on the second patent (EP1308455) at suit in the action. This patent was held to be invalid at the EPO following opposition, and this decision is presently under appeal before the EPO Boards of Appeal.

Following production of trastuzumab in a cell line, the asparagine amino acids in the protein can spontaneously degrade to aspartate (an acidic amino acid). This leads to a mixed population of native trastuzumab and the so-called 'acidic variants' of trastuzumab. Certain acidic variants are less effective than native trastuzumab because they bind to their target (HER2) less tightly. The patent discloses a cationic exchange chromatography method of separating acidic variants and native trastuzumab, using a special 'reverse wash' step. This step increases the yield of native trastuzumab because the acidic variants normally co-purify to an extent with native trastuzumab. The patent's claims are directed to a composition comprising a mixture of an anti-HER2 antibody and one or more acidic variants thereof, wherein the acidic variants make up less than 25% of the mixture.

The parties' arguments and the court's judgment


Hospira contended that the claims were not novel over a prior Genentech patent publication describing pharmaceutical compositions of trastuzumab. The publication discloses the separation of native and acidic variants of trastuzumab, and reports that native trastuzumab made up 82% of the protein content of the sample of trastuzumab tested. Hence, the maximum level of acidic variants in this sample was 18%, and so the report of this sample was considered to be a disclosure of a composition according to claim 1.

The judge therefore found that claim 1, and a number of the patent's dependent claims, lacked novelty.

Inventive step

The claims were alleged to lack inventive step over slides presented by a Genentech employee at a conference.

The slides disclosed the fact that trastuzumab was being manufactured on a large scale, disclosed analytical chromatograms showing separation of native and acidic variants of trastuzumab, and noted that the acidic variants were not as effective as the native antibody. The Judge considered that in light of this disclosure it was obvious for the skilled person to seek to reduce the amount of undesirable acidic variants in the composition. Further, he found that it would have been possible to do so because the purification scheme discussed in the slides indicated that the native and acidic forms could be separated.

The slides did not disclose the reverse wash step used in the patent. Genentech's expert had stated that separation of the native and acidic variants of trastuzumab during large-scale production without the reverse wash step would be inefficient and that, as the yield would be so poor, this method would not be used by the skilled person. The Judge considered that this was not relevant; the fact that it would be technically possible at all for the skilled person to produce a composition which fell within the scope of the claims was what was important, even if to do so was not a commercially sound decision. The Judge also stated that:

"An improvement in yield might very well provide the basis for an inventive step in the context of a new method for of carrying out an industrial process but it seems to me that it does not confer inventiveness on a product which is defined in such a way that it can be made by any process, whatever the yield."

Accordingly, the Judge found all claims of the patent to be obvious.


Hospira also requested a declaration of non-infringement, stating that the trastuzumab in batches of their product contained 25-29% acidic variants. The Judge considered that the upper limit of claim 1 of the patent ("less than 25%") was 24.5%, and accordingly found that Hospira's formulations fell outside of the scope of the claims. On this basis, the declaration was granted.


The patent was revoked for lacking novelty over Genentech's own earlier patent publication, and for lacking inventive step over a conference disclosure by one of its own employees.

In reaching its conclusions, the Court applied the established principles of assessing the subject matter based on the wording of the claim. The arguments by the parties in court included many nuances, including the scale of purification, but at the end of the day the Judge decided that it was possible and obvious to make compositions as set out in the claim. The Judge noted that some methods of making the compositions may be more efficient than others, but what matters is whether it was possible to arrive at the claimed subject matter, not whether or not it would be tedious or commercially sensible to do so.

The consequence of this judgment is to indicate that, provided that it was known or was obvious that particular protein species can be separated from one another, merely reciting the percentage of the purified protein in the resulting composition is unlikely to be found to be inventive. This judgment may therefore obstruct another well-trodden pathway for obtaining follow-on protection in the UK.

For further information please contact:

For more information, please contact

Carpmaels & Ransford LLP is a leading firm of European patent and trade mark attorneys based in London. For more information about our firm and our practice, please visit our website at

This Briefing Note was first published in the IAM IP Newsletter.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions